Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

• Status: Terminated
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving drugs in different combinations may kill more cancer cells. It is not yet know which treatment regimen is more effective in treating Hodgkin lymphoma.

PURPOSE: This phase III trial is studying three different therapy regimens to compare how well they work in treating patients with previously untreated Hodgkin lymphoma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: French Innovative Leukemia Organisation
• Treatments: Bleomycin; Carmustine; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Gemcitabine; Ifosfamide; Liposomal doxorubicin; Melphalan; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Mitoguazone; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Vincristine; Vindesine; Vinorelbine

Criteria

INCLUSION CRITERIA

• Life expectancy > 3 months

• LVEF normal

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• Must be able to undergo follow-up for ≥ 15 years

• No impaired cardiac function that would preclude the administration of an anthracycline

• No other prior or concurrent malignancy, except for carcinoma in situ of the cervix or basal cell skin cancer

• No respiratory, kidney, or liver failure or other severe clinical insufficiency that would preclude study treatment

• No HIV or hepatitis B virus positivity

• No other disease that would preclude treatment with chemotherapy or radiotherapy

EXCLUSION CRITERIA:

• No concurrent participation in another experimental trial